Massachusetts Institute of Technology-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Massachusetts Institute of Technology - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014370
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:86
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Massachusetts Institute of Technology (MIT) is a research university that provides contract research and education. The institute offers education in the areas of computer science, biology, aeronautics, mechanical engineering, civil engineering, economics, electrical engineering, literature, architecture, chemistry, mathematics, political science, history, linguistics, nuclear science, physics, and music and theater arts. It conducts research in the fields of neuroscience, humanities, anthropology, cancer, astronomy, oceanography, nuclear science, cognitive science, nanoscience, and nanotechnology. MIT provides services to its students like student information system, academic calendar, libraries, freshman advising, and student disabilities services. The institute offers extracurricular activities like sports, music, dance, arts, and athletics. MIT is headquartered, Cambridge, Massachusetts, the US.

Massachusetts Institute of Technology – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Massachusetts Institute of Technology, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Massachusetts Institute of Technology, Medical Devices Deals, 2011 to YTD 2017 10
Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deal Details 14
Partnerships 14
CureMeta Enters into Research Agreement with Whitehead Institute for Biomedical Research 14
AstraZeneca Enters into Research Agreement with Broad Institute and Whitehead Institute 15
White Head Institute And Biogen Idec Enter Into Reasearch Agreement 16
Licensing Agreements 17
Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, Massachusetts Institute of Technology and University of Iowa 17
Cognito Therapeutics Enters into Licensing Agreement with Massachusetts Institute of Technology 19
Frequency Therapeutics Receives Intellectual Property Rights from MIT and Harvard Medical School 20
Juniper Pharma Enters into Licensing Agreement with Harvard Medical, Massachusetts General Hospital and Massachusetts Institute of Technology 21
Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, and Massachusetts Institute of Technology 23
SQZ Biotec Enters into License Agreement with Massachusetts Institute of Technology 25
Visterra Enters into Licensing Agreement with MIT for Dengue Virus Antibodies 26
Cell2B Enters into Licensing Agreement with Massachusetts Institute of Technology and Instituto Superior Tecnico 27
Enumeral Biomedical Amends Licensing Agreement with Massachusetts Institute of Technology 28
Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard, MIT, Wageningen University, and University of Tokyo 29
Columbia Labs Enters into Licensing Agreement for IVR Technology 31
Gensight Biologics Enters into Option Agreement with Massachusetts Institute of Technology 32
MetaStat Enters Into Licensing Agreements For Alternative Splicing Program 33
Syros Pharma Enters into Licensing Agreement with Whitehead Institute 35
Syros Pharma Enters into Licensing Agreement with Dana-Farber and Whitehead 36
Reflexion Pharma Enters into Licensing Agreement with Whitehead Institute for Biomedical Research 38
Pervasis Therapeutics Enters Into Licensing Agreement With Massachusetts Institute 39
Massachusetts Institute of Technology – Key Competitors 41
Massachusetts Institute of Technology – Key Employees 42
Massachusetts Institute of Technology – Locations And Subsidiaries 43
Head Office 43
Other Locations & Subsidiaries 43
Recent Developments 44
Government and Public Interest 44
Oct 12, 2017: New technique scours the genome for genes that combat disease 44
Sep 04, 2017: Study suggests simple way to predict preterm births 46
Jul 20, 2017: Study Predicts Heart Cells’ Response to Dwindling Oxygen 48
Jul 19, 2017: DARPA: Building the Safe Genes Toolkit 50
Jul 12, 2017: Antibiotic Nanoparticles Fight Drug-resistant Bacteria 53
Mar 20, 2017: Tethered nanoparticles make tumor cells more vulnerable 55
Feb 10, 2017: U.S. Scientists Receive Inaugural $87 Million Grand Challenge Awards To Accelerate Global Progress To Beat Cancer Sooner 57
Sep 22, 2016: Kenneth Rainin Foundation Awards Over $3 Million to High-Risk, High Reward Inflammatory Bowel Disease Research Projects 58
Sep 08, 2016: New Vaccination Strategies Successfully Coach Immune System to Make Powerful HIV-Neutralizing Antibodies 60
Aug 15, 2016: New enzyme-mapping advance could help drug development 62
Jul 04, 2016: Engineers design programmable RNA vaccines 64
Jun 08, 2016: Drug candidate shrinks tumor when delivered by plant virus nanoparticle 66
May 02, 2016: New drug-delivery approach holds potential for treating obesity 68
Apr 21, 2016: Critical immunotherapy target marks dysfunctional regulatory T cells in brain cancer 70
Feb 01, 2016: Curing disease by repairing faulty genes : Massachusetts Institute of Technology 71
Jan 25, 2016: Researchers Show Novel Material Encapsulated Human Islet Cells Can Halt Type 1 Diabetes for Six Months 73
Jan 12, 2016: New NIH awards will support development of therapeutic alternatives to traditional antibiotics 74
Jan 06, 2016: In a step toward personalized drug testing, researchers coax human stem cells to form complex tissues 76
Product News 78
Nov 16, 2016: Next-generation biomaterial being developed to treat bleeding 78
May 02, 2016: Massachusetts Institute of Technology: Fat-fighting nanoparticles 79
Apr 18, 2017: Long-lasting drug delivery system may help decrease the spread of malaria 81
Apr 06, 2016: Engineers develop a pill for long-term drug release 82
Feb 27, 2017: New technology offers fast peptide synthesis 84
Appendix 86
Methodology 86
About GlobalData 86
Contact Us 86
Disclaimer 86

List of Tables
Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Key Facts 2
Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Massachusetts Institute of Technology, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Massachusetts Institute of Technology, Deals By Therapy Area, 2011 to YTD 2017 9
Massachusetts Institute of Technology, Medical Devices Deals, 2011 to YTD 2017 10
Massachusetts Institute of Technology, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
CureMeta Enters into Research Agreement with Whitehead Institute for Biomedical Research 14
AstraZeneca Enters into Research Agreement with Broad Institute and Whitehead Institute 15
White Head Institute And Biogen Idec Enter Into Reasearch Agreement 16
Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, Massachusetts Institute of Technology and University of Iowa 17
Cognito Therapeutics Enters into Licensing Agreement with Massachusetts Institute of Technology 19
Frequency Therapeutics Receives Intellectual Property Rights from MIT and Harvard Medical School 20
Juniper Pharma Enters into Licensing Agreement with Harvard Medical, Massachusetts General Hospital and Massachusetts Institute of Technology 21
Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard University, and Massachusetts Institute of Technology 23
SQZ Biotec Enters into License Agreement with Massachusetts Institute of Technology 25
Visterra Enters into Licensing Agreement with MIT for Dengue Virus Antibodies 26
Cell2B Enters into Licensing Agreement with Massachusetts Institute of Technology and Instituto Superior Tecnico 27
Enumeral Biomedical Amends Licensing Agreement with Massachusetts Institute of Technology 28
Editas Medicine Enters into Licensing Agreement with Broad Institute, Harvard, MIT, Wageningen University, and University of Tokyo 29
Columbia Labs Enters into Licensing Agreement for IVR Technology 31
Gensight Biologics Enters into Option Agreement with Massachusetts Institute of Technology 32
MetaStat Enters Into Licensing Agreements For Alternative Splicing Program 33
Syros Pharma Enters into Licensing Agreement with Whitehead Institute 35
Syros Pharma Enters into Licensing Agreement with Dana-Farber and Whitehead 36
Reflexion Pharma Enters into Licensing Agreement with Whitehead Institute for Biomedical Research 38
Pervasis Therapeutics Enters Into Licensing Agreement With Massachusetts Institute 39
Massachusetts Institute of Technology, Key Competitors 41
Massachusetts Institute of Technology, Key Employees 42
Massachusetts Institute of Technology, Subsidiaries 43

★海外企業調査レポート[Massachusetts Institute of Technology-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Mexco Energy Corp (MXC):石油・ガス:M&Aディール及び事業提携情報
    Summary Mexco Energy Corp (Mexco Energy) is an oil and gas company that offers exploration, acquisition, production, and development of crude oil, natural gas, condensate liquids, and natural gas liquids. The company acquires producing and non-producing oil and gas leases from landowners and leaseho …
  • Toyo Suisan Kaisha, Ltd. (2875):企業の財務・戦略的SWOT分析
    Toyo Suisan Kaisha, Ltd. (2875) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Westwater Resources, Inc.:企業の戦略・SWOT・財務情報
    Westwater Resources, Inc. - Strategy, SWOT and Corporate Finance Report Summary Westwater Resources, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • PharmAust Ltd (PAA)-製薬・医療分野:企業M&A・提携分析
    Summary PharmAust Ltd (PharmAust) is a drug discovery and development company which provides human and veterinary proprietary medicines to treat different types of cancers. The company provides specialized medicinal and synthetic chemistry services. It specializes in bio defense and laboratory suppo …
  • Aptiv Plc
    Aptiv Plc - Strategy, SWOT and Corporate Finance Report Summary Aptiv Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • John Keells Hotels Plc:企業の戦略・SWOT・財務分析
    John Keells Hotels Plc - Strategy, SWOT and Corporate Finance Report Summary John Keells Hotels Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Rollins Inc (ROL):企業の財務・戦略的SWOT分析
    Summary Rollins Inc (Rollins) is a consumer and commercial service provider that provides essential pest control services and protection against termite damage, rodents and insects. The company provides services through its international franchises. It also offers customized services to its clients …
  • Nuformix Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Nuformix Ltd (Nuformix) is a provider of pharmaceutical cocrystallisation products. The company develops and manufactures products in reprofiling, supergenerics and emerging markets areas. It offers methodologies for rational solid form discovery; and provides technologies for rapid solid fo …
  • Ngai Hing Hong Co Ltd (1047):企業の財務・戦略的SWOT分析
    Ngai Hing Hong Co Ltd (1047) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Abeona Therapeutics Inc (ABEO):医療機器:M&Aディール及び事業提携情報
    Summary Abeona Therapeutics Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc., is a biopharmaceutical company that develops and delivers gene therapy and plasma-based products for severe and life-threatening rare diseases. The company’s lead programs include ABO-101 and ABO-102 adeno-associ …
  • Hornbeck Offshore Services Inc (HOS):石油・ガス:M&Aディール及び事業提携情報
    Summary Hornbeck Offshore Services Inc (HOS) is a provider of marine services. The company offers marine transportation, subsea installation and accommodation support services to exploration and production, oilfield service, offshore construction and the US military customers. It supplies vessels, t …
  • The New York Times Company (NYT):企業の財務・戦略的SWOT分析
    The New York Times Company (NYT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Biomm SA (BIOM3):製薬・医療:M&Aディール及び事業提携情報
    Summary Biomm SA (Biomm), formerly Savicevic Participacoes SA is a biopharmaceutical company that research, develops, produces and markets biomedicines. The company develops processes for the production of active pharmaceutical ingredients and enzymes used in the production of biofuels. It licenses …
  • Danske Bank A/S:企業のM&A・事業提携・投資動向
    Danske Bank A/S - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Danske Bank A/S Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestm …
  • Bioasis Technologies Inc (BTI):企業の財務・戦略的SWOT分析
    Summary Bioasis Technologies Inc (BTI) operates as a developer and commercialize of pharmaceutical products and diagnostic technologies for central nervous system diseases and disorders. The company’s transcend program describes the proprietary carrier, p97 to deliver therapeutics and imaging agents …
  • Opiant Pharmaceuticals Inc (OPNT):企業の財務・戦略的SWOT分析
    Opiant Pharmaceuticals Inc (OPNT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Origin Energy Limited:企業の戦略・SWOT・財務情報
    Origin Energy Limited - Strategy, SWOT and Corporate Finance Report Summary Origin Energy Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Dubai Islamic Bank P.J.S.C.:戦略・SWOT・企業財務分析
    Dubai Islamic Bank P.J.S.C. - Strategy, SWOT and Corporate Finance Report Summary Dubai Islamic Bank P.J.S.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • National Grid Plc (NG):石油・ガス:M&Aディール及び事業提携情報
    Summary National Grid Plc (National Grid) is an energy utility. It transmits and distributes electricity and gas. The company owns and operates electricity and gas transmission and distribution networks; and is also the system operator for the Scottish networks. National Grid provides installation a …
  • H.I.S. Co., Ltd.:企業の戦略・SWOT・財務情報
    H.I.S. Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary H.I.S. Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆